Eventually, the up-regulated SOX2 increased the survival and proportion of CSCs through CDK6 or FGFR1/2, depending on the resistant DLBCL cell subtype, thus inducing resistance. The gene discussed is CDK6; the disease is diffuse large B-cell lymphoma.